The AFL-AGC Building Trades Welfare plan alleges that Pfizer and Ranbaxy delayed a generic version of Lipitor for 20 months. The plan has brought a proposed class-action lawsuit in U.S. District Court, Southern District of New York (Manhattan). Plaintiffs claim that Ranbaxy, the manufacturer of the generic, entered into an anticompetitive scheme with Pfizer, whose patent for Lipitor expired on March 24, 2010.
Source: Bloomberg
Related content: Reversing the Trend? The Possibility that Rule Changes May Lead to Fewer Reverse Payments in Pharma Settlements (Anne Layne-Farrar, Compass Lexecon)
Featured News
Alaska Airlines’ Hawaiian Acquisition Faces Antitrust Scrutiny
Dec 6, 2023 by
CPI
Ulmer & Greensfelder Merge to Form UB Greensfelder
Dec 6, 2023 by
CPI
Apple’s iMessage May Be Exempt from New EU Regulations
Dec 6, 2023 by
CPI
UK Watchdog Warns Firms on AI Privacy Compliance
Dec 6, 2023 by
CPI
FTC Mounts Second Challenge to Microsoft’s Activision Buy Despite Closed Deal
Dec 6, 2023 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Horizontal Competition: Mergers, Innovation & New Guidelines
Nov 30, 2023 by
CPI
Innovation in Merger Control
Nov 30, 2023 by
CPI
Making Sense of EU Merger Control: The Need for Limiting Principles
Nov 30, 2023 by
CPI
Sustainability Agreements in the EU: New Paths to Competition Law Compliance
Nov 30, 2023 by
CPI
Merger Control and Sustainability: A New Dawn or Nothing New Under the Sun?
Nov 30, 2023 by
CPI